tESCS for Upper Limb Rehab in Spinal Cord Injury

Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorNHS Greater Glasgow and Clyde

About this trial

Regaining hand and arm function is an important step towards regaining independence following high-level spinal cord injury (tetraplegia). The delivery of small electrical pulses over the skin above the spinal cord, called transcutaneous spinal cord stimulation (tESCS), appears to improve the arm and hand function of people who have had tetraplegia for several years when delivered at the same time as upper limb therapy. However, tESCS has not been tested in people who have a new spinal cord injury. It should be straightforward to deliver tESCS during standard upper limb therapy sessions to inpatients receiving primary rehabilitation. The investigators want to test the practical aspects of delivering this intervention and also to compare recovery between a group of people who only receive upper limb therapy and a group who receive upper limb therapy and tESCS. If successful, tESCS could in the future be used as part of regular therapy following an acute spinal cord injury. Benefits could include faster and better recovery, reduced stay in hospital, and reduced NHS costs.

Eligibility criteria

Qualifiers

Aged 18 years or over, both sexes.

At least 6 weeks post-implant (in participants having a surgery for an implant to stabilise the spine).

ISNCSCI upper extremity motor score between 5 and 30 (both arms/hands)

GRASSP-strength score >=15 & <70

Disqualifiers

Unstable cervical spine injury

Needing ventilation assistance during daytime

Any implanted active metallic device without unconfirmed MRI compatibility (in our previous studies, we safely applied tESCS to participants with MRI-compatible devices/implants)

Pregnancy and/or lactation.

Trial design

Treatments tested in this trial

  • Transcutaneous spinal cord stimulation (tESCS) active group
  • Sham transcutaneous spinal cord stimulation (tESCS)

Treatment groups

20 Participants
are divided into 2 treatment groups

Sponsors and collaborators

NHS Greater Glasgow and Clyde

Lead sponsor

University of Glasgow

Collaborator

The Queen Elizabeth Hospital

Collaborator